[Form 4] LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock Insider Trading Activity

Rhea-AI Filing Summary

LifeMD, Inc. – Form 4 insider activity

Chief Financial Officer Marc David Benathen disclosed two open-market sales of LifeMD (ticker LFMD) common stock. On 06/16/2025 he sold 75,000 shares at a weighted-average price of $13.0926 (individual trades between $12.57-$13.57). On 06/17/2025 he sold an additional 50,000 shares at a weighted-average price of $14.0099 (trades between $14.00-$14.07). Total shares disposed: 125,000.

After the transactions, Benathen’s direct ownership decreased from 464,554 to 339,554 shares, a reduction of roughly 26.9 % of his previously reported direct stake. No purchases or derivative security transactions were reported in Table II. The filing, signed on 06/18/2025, does not indicate the use of a Rule 10b5-1(c) trading plan.

This Form 4 provides investors with updated information on insider ownership and trading activity by a key executive officer.

Positive

• None.

Negative

• CFO disposed of 125,000 common shares, reducing his direct stake by approximately 26.9 %.
• No purchases or 10b5-1 trading plan disclosure, which may negatively influence investor sentiment.

Insights

Financial Analyst

TL;DR: CFO sold 125k shares (≈27% stake) at $13–14; no purchases disclosed; insider selling often viewed as a negative signal.

Insider activity filings matter because they reveal management’s confidence in the company’s prospects. Here, LifeMD’s CFO disposed of 125,000 shares across two consecutive days, trimming his direct holdings to 339,554 shares. At the reported weighted-average prices, gross proceeds total roughly $1.69 million. While executives can sell for many personal reasons, a sale of this magnitude—over a quarter of the officer’s position—can be interpreted by some investors as reduced conviction or a desire to diversify. No mitigating factors such as option exercise, tax settlement, or a disclosed 10b5-1 plan appear in the filing. Consequently, the market may perceive this transaction as modestly negative.

Corporate Governance Expert

TL;DR: Significant officer disposal without 10b5-1 plan disclosure raises governance and perception considerations.

From a governance standpoint, transparency around insider transactions is critical. The filing satisfies SEC Form 4 requirements, giving detailed price ranges and post-sale ownership. However, large discretionary sales by C-suite members can draw shareholder scrutiny, particularly when they are not linked to scheduled trading plans. Investors will likely monitor future filings to determine whether this is an isolated liquidity event or part of a broader trend among executives. The transaction is therefore classified as impactful and potentially negative for sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benathen Marc David

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S		75,000	D	$13.0926(1)	389,554	D
Common Stock	06/17/2025		S		50,000	D	$14.0099(2)	339,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.57 and $13.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 and $14.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above.

	/s/ Marc David Benathen	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many LifeMD (LFMD) shares did the CFO sell in this Form 4?

Marc David Benathen sold 125,000 common shares across two transactions.

On what dates were the LifeMD shares sold?

The transactions occurred on 06/16/2025 (75,000 shares) and 06/17/2025 (50,000 shares).

What prices did the shares trade at?

Weighted-average prices were $13.0926 on 06/16 and $14.0099 on 06/17, with ranges detailed in the filing.

How many LifeMD shares does the CFO own after the sale?

Following the transactions, he directly owns 339,554 common shares.

Were any derivative securities reported in Table II?

No. The filing shows no derivative securities acquired or disposed of during the period.